Search Within

Mark Kris

Formats
  1. Journal Article (480)
  2. Meeting Abstract (356)
  3. Conference Paper (16)
  4. Book Section (9)
  5. Review (6)
  6. Guidelines (2)
  7. Editorial (1)
  8. Miscellaneous (1)
  9. Research Letter (1)
Groups
  1. Department of Medicine (872)
  2. Solid Tumor Oncology Division (872)
  3. Thoracic Oncology (872)
  4. Department of Pathology and Laboratory Medicine (319)
  5. GSK Faculty (292)
  6. Human Oncology and Pathogenesis Program (225)

More Groups

People
  1. Gregory Riely (222)
  2. Marc Ladanyi (190)
  3. Vincent Miller (172)
  4. Valerie Rusch (130)
  5. Maria Arcila (123)
  6. Jamie Chaft (107)

More People

Years
  1. 2025 (7)
  2. 2024 (18)
  3. 2023 (27)
  4. 2022 (21)
  5. 2021 (21)
  6. 2020 (25)

More Years

Publications
  1. Journal of Clinical Oncology (235)
  2. Journal of Thoracic Oncology (131)
  3. Clinical Cancer Research (65)
  4. Cancer (33)
  5. Lung Cancer (31)
  6. Annals of Oncology (25)

More Publications

Publishers
  1. American Society of Clinical Oncology (253)
  2. Elsevier Inc. (179)
  3. American Association for Cancer Research (105)
  4. Oxford University Press (48)
  5. Wiley Blackwell (36)
  6. Elsevier Ireland Ltd. (30)

More Publishers

Results (872)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • YES1 amplification as a mechanism of acquired resistance (AR) to EGFR tyrosine kinase inhibitors (TKIs) identified by a transposon mutagenesis screen and clinical genomic testing
    Meeting Abstract

    Fan, P. D.; Narzisi, G.; Jayaprakash, A.; Venturini, E.; Robine, N.; Smibert, P.; Germer, S.; Jordan, E.; Wang, L.; Jungbluth, A. A.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Baseline frequency of brain metastases and outcomes with multikinase inhibitor therapy in patients with RET-rearranged lung cancers
    Meeting Abstract

    Drilon, A. E.; Filleron, T.; Bergagnini, I.; Milia, J.; Hatzoglou, V.; Velcheti, V.; Besse, B.; Mok, T.; Awad, M. M.; Wolf, J.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Retrospective analysis of clinical outcomes of early stage ALK-positive (ALK+) non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Dagogo-Jack, I.; Santini, F.; Eng, J.; Yeap, B. Y.; Izar, B.; Chin, E.; Litvak, A.; Jones, D. R.; Kris, M. G.; Shaw, A. T.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment
    Meeting Abstract

    Basch, E. M.; Deal, A. M.; Dueck, A. C.; Bennett, A. V.; Atkinson, T. M.; Scher, H. I.; Kris, M. G.; Hudis, C. A.; Sabbatini, P.; Dulko, D.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Response to osimertinib following treatment with EGF816 in patients with T790M EGFR mutant NSLCLC
    Meeting Abstract

    Arbour, K. C.; Sequist, L. V.; Piotrowska, Z.; Kris, M. G.; Paik, P. K.; Ni, A.; Plodkowski, A.; Riely, G.; Yu, H. A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Antiemetics: American Society of Clinical Oncology clinical practice guideline update summary
    Journal Article

    Hesketh, P. J.; Bohlke, K.; Kris, M. G.
    Journal of Oncology Practice (2017)

    Fulltext@MSK | Save
  • Phase 1 study of ramucirumab or necitumumab in combination with osimertinib (AZD9291) in advanced T790M-positive EGFR-mutant NSCLC
    Meeting Abstract

    Planchard, D.; Kris, M.; Besse, B.; Hozak, R.; He, S.; Gan, F.; Wolff, K.; Chao, B.; Yu, H.
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • A phase II study of atezolizumab as neoadjuvant and adjuvant therapy in patients (pts) with resectable non small cell lung cancer (NSCLC)
    Meeting Abstract

    Owen, D.; Bunn, P. Jr; Johnson, B.; Kwiatkowski, D.; Kris, M.; Wistuba, I.; Gandhi, M.; Phan, S.; Shames, D.; Schulze, K.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Neratinib +/- temsirolimus in HER2-mutant lung cancers: An international, randomized phase II study
    Meeting Abstract

    Gandhi, L.; Besse, B.; Mazieres, J.; Waciar, S.; Cortot, A.; Barlesi, F.; Quoix, E.; Otterson, G.; Ettinger, D.; Horn, L.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save
  • Improved small cell lung cancer (SCLC) response rates with veliparib and temozolomide: Results from a phase II trial
    Meeting Abstract

    Byers, L. A.; Krug, L.; Waqar, S.; Dowlati, A.; Hann, C.; Chiappori, A.; Owonikoko, T.; Woo, K.; Bensman, Y.; Hurtado, B.; more...
    Journal of Thoracic Oncology (2017)

    Fulltext@MSK | Save